Showing 71 - 80 of 36,106
Objective: To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. Design and setting:...
Persistent link: https://www.econbiz.de/10005243104
Persistent link: https://www.econbiz.de/10005243105
Objective: To offer cost estimates of urinary incontinence (UI) in the general population based on prospectively collected data. Design: We analysed individual costs in a sample of women with UI who were identified in the framework of a cross-sectional study on the prevalence of UI in women aged...
Persistent link: https://www.econbiz.de/10005243106
Pharmaceutical expenditure is rising more rapidly than the general inflation rate in most advanced countries. One strategy that has been introduced to control pharmaceutical costs is reference-based pricing (RBP). Its potential is restricted to those specific segments of the drug market where...
Persistent link: https://www.econbiz.de/10005243107
Background: Use of unmodified interferon alpha-2a in chronic hepatitis C is associated with impaired health-related quality of life during therapy. Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a. Objectives: To compare...
Persistent link: https://www.econbiz.de/10005243108
Patient-reported outcomes (PROs), including resource utilisation, productivity and quality of life, are important outcomes in the field of migraine. Clinical trials have begun to incorporate PROs; however, not all research questions can be answered fully within the framework of a clinical trial...
Persistent link: https://www.econbiz.de/10005243109
Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...
Persistent link: https://www.econbiz.de/10005243110
Objective: To examine the medical costs and effectiveness of acute treatment with imipramine versus acute treatment plus 2 different maintenance therapies for panic disorder. Methods: A clinical decision model was constructed to estimate 18-month costs and outcomes associated with these...
Persistent link: https://www.econbiz.de/10005243112
Cost-effectiveness analysis has gained status over the last 15 years as an important tool for assisting resource allocation decisions in a budget-limited environment such as healthcare. Randomised (multicentre) multinational controlled trials are often the main vehicle for collecting primary...
Persistent link: https://www.econbiz.de/10005243113
Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other antidepressant in the world. Prozac(R) has also become a household name. In this article we examine the circumstances that surround this success, and the evidence base that supports it....
Persistent link: https://www.econbiz.de/10005243117